NCT05369208已完成3 期
An Open-label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic Immune Thrombocytopenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sobi, Inc.
- 入组人数
- 19
- 试验地点
- 27
- 主要终点
- Cumulative Number of Weeks of Platelet Response
研究概览
简要总结
Evaluate the efficacy, safety, and PK of avatrombopag given for 26 weeks in Japanese adults with chronic immune thrombocytopenia (ITP).
详细描述
This Phase 3, multicenter, open label study will evaluate the efficacy, safety, and population pharmacokinetics (PK) of avatrombopag in Japanese adults with chronic ITP. At least 19 subjects will be enrolled. The study will consist of 3 phases: Pre-enrollment, Primary Investigation, and Extension Phase until market authorization in Japan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has a confirmed diagnosis of chronic immune thrombocytopenia (ITP) (≥12 months duration) and has had an insufficient response to a previous ITP treatment, in the opinion of the Investigator.
- •Subject has an average of 2 platelet counts <30×10^9/L (no single count can be >35×10^9/L). The 2 samples must be obtained ≥48 hours and ≤2 weeks apart.
排除标准
- •Subjects with known secondary immune thrombocytopenia (e.g., with known Helicobacter pylori-induced ITP, subjects infected with known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) or subjects with known systemic lupus erythematosus).
- •Subjects with known inherited thrombocytopenia (e.g., Myosin Heavy Chain 9 (MYH-9) disorders) or hereditary thrombophilic disorders (e.g., Factor V Leiden, antithrombin III deficiency).
- •History of myelodysplastic syndrome (MDS).
- •History of arterial or venous thrombosis.
- •Subjects with a history of significant cardiovascular disease (e.g., congestive heart failure (CHF) New York Heart Association Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [e.g., atrial fibrillation], angina, coronary artery stent placement, angioplasty, coronary artery bypass grafting).
- •Subjects with a history of cirrhosis, portal hypertension, or chronic active hepatitis.
- •Subjects with concurrent malignant disease or receiving cytotoxic chemotherapy for a reason other than ITP treatment.
- •Use of immunoglobulins (IVIg and anti-D) or corticosteroid rescue therapy within 1 week of Day 1/Baseline.
- •Splenectomy or use of rituximab within 12 weeks of Day 1/Baseline.
- •Use of romiplostim or eltrombopag within 1 week of Day 1/Baseline.
- •Use of chronic corticosteroid treatment or azathioprine within 4 weeks of Day 1/Baseline, unless receiving a stable dose for at least 4 weeks.
- •Use of mycophenolate mofetil, cyclosporin A, or danazol within 4 weeks of Day 1/Baseline, unless receiving a stable dose for at least 12 weeks.
- •Use of cyclophosphamide or vinca alkaloid regimens within 4 weeks of Baseline Visit.
- •Currently receiving moderate or strong dual inhibitors/inducers of CYP2C9 and CYP3A
- •Serum creatinine ≥1.5× the upper limit of normal (ULN).
- •Serum bilirubin ≥2×ULN.
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3×ULN.
- •Females who are pregnant (positive beta-human chorionic gonadotropin (β-hCG) test) or breastfeeding.
- •Received treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) before Day 1/Baseline.
研究组 & 干预措施
Avatrombopag
Other
Avatrombopag 20 mg oral tablet
干预措施: Avatrombopag Oral Tablet (Drug)
结局指标
主要结局
Cumulative Number of Weeks of Platelet Response
时间窗: 26 weeks of active treatment
Cumulative number of weeks in which the platelet count is ≥50×10\^9/L during 26 weeks of treatment in the absence of rescue therapy.
次要结局
- Response Rate at Day 8(Day 8)
研究者
研究点 (27)
Loading locations...
相似试验
终止
3 期
Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical ProcedureThrombocytopeniaNCT03326843Sobi, Inc.4
撤回
3 期
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 MonthsImmune ThrombocytopeniaNCT05046327Sobi, Inc.
已完成
3 期
Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)Chronic ThrombocytopeniaImmune ThrombocytopeniaNCT01438840Eisai Inc.49
Unknown
2 期
Avatrombopag Usage in NSAADrug EffectAplastic AnemiaNCT04728789Peking Union Medical College Hospital40
已完成
4 期
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or RomiplostimImmune ThrombocytopeniaNCT04638829Sobi, Inc.60